BioCentury
ARTICLE | Product Development

Moderna COVID-19 vaccine Phase III will be conducted in new NIH-managed trial network

June 11, 2020 12:07 PM UTC
Updated on Jun 11, 2020 at 11:45 PM UTC

Strategies for late-stage clinical testing of COVID-19 vaccine candidates are coming into focus with the announcement of a July start for a Phase III trial of Moderna’s mRNA-1273.

The vaccine candidate from Moderna Inc. (NASDAQ:MRNA) will be tested in a coronavirus prevention network that NIH’s National Institute of Allergy and Infectious Diseases is overseeing, a NIAID spokesperson told BioCentury. ...